Surinabant

Surinabant (SR147778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis.[1] It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several CB1 antagonists or inverse agonists on the market or under development for this application,[2] so surinabant is at present mainly being developed as an anti-smoking drug,[3] with possible application in the treatment of other addictive disorders such as alcoholism.[4][5] Other potential applications such as treatment of ADHD have also been proposed.[6]

Surinabant
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H23BrCl2N4O
Molar mass522.27 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

A dose ranging study was done for smoking cessation[7] in 2012; it did not improve success rate, but reduced weight gain. Inhibition of THC effects on heart rate was seen at 20 mg and 60 mg but not 5 mg.[8]

See also

References
  1. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, et al. (September 2004). "SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization". The Journal of Pharmacology and Experimental Therapeutics. 310 (3): 905–14. doi:10.1124/jpet.104.067884. PMID 15131245. S2CID 25640461.
  2. Doggrell SA (March 2005). "Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?". Expert Opinion on Investigational Drugs. 14 (3): 339–42. doi:10.1517/13543784.14.3.339. PMID 15833065. S2CID 33937749.
  3. Lamota L, Bermudez-Silva FJ, Marco EM, Llorente R, Gallego A, Rodríguez de Fonseca F, Viveros MP (January 2008). "Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats". Neuropharmacology. 54 (1): 194–205. doi:10.1016/j.neuropharm.2007.07.004. PMID 17720206. S2CID 22293050.
  4. Gessa GL, Serra S, Vacca G, Carai MA, Colombo G (2005). "Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats". Alcohol and Alcoholism. 40 (1): 46–53. doi:10.1093/alcalc/agh114. PMID 15582988.
  5. Lallemand F, De Witte P (July 2006). "SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats". Alcohol. 39 (3): 125–34. doi:10.1016/j.alcohol.2006.08.001. PMID 17127132.
  6. Louis C, Terranova JP, Decobert M, Bizot JC, Françon D, Alonso R, Cohen C, Griebel G (2005). "Surinabant, a new CB1 receptor antagonist, displays efficacy in animal models of attention deficit/hyperactivity disorder". Behavioural Pharmacology. 16: S42. doi:10.1097/00008877-200509001-00133.
  7. Tonstad S, Aubin HJ (July 2012). "Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial". Journal of Psychopharmacology. 26 (7): 1003–9. doi:10.1177/0269881111431623. PMID 22219220. S2CID 39145361.
  8. Klumpers LE, Roy C, Ferron G, Turpault S, Poitiers F, Pinquier JL, et al. (July 2013). "Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans". British Journal of Clinical Pharmacology. 76 (1): 65–77. doi:10.1111/bcp.12071. PMC 3703229. PMID 23278647.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.